ASPI

ASP Isotopes (NASDAQ:ASPI) CEO Paul Mann outlined the company’s plans to expand its isotope-enrichment, radiopharmacy and helium businesses, while targeting more than $300 million in EBITDA by 2031.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

COSTA MESA, Calif., Sept. 17, 2026 /PRNewswire/ -- The following statement is being issued by Simpluris, Inc., court-appointed settlement administrator, regarding Mark Leone v. ASP Isotopes Inc., et al., Case No. 1:24-cv-9253-CM.

DALLAS, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc.

ASP Isotopes (NASDAQ:ASPI) expects several of its business units to enter commercial production or expand output over the next six months, with Chief Executive Officer Paul Mann highlighting progress in helium, liquefied natural gas, stable isotopes and…

In July 2026, ASP Isotopes Inc. filed a shelf registration to offer 23,160,682 shares of common stock, with an aggregate value of US$106.08 million. We will now examine how ASP Isotopes’ broader investment narrative is shaping up.

ASP Isotopes (ASPI) has filed a shelf registration for up to US$106.1 million of common stock, covering 23,160,682 shares.